

=> b reg
 FILE 'REGISTRY' ENTERED AT 11:19:02 ON 15 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2008 HIGHEST RN 1049627-95-3
 DICTIONARY FILE UPDATES: 14 SEP 2008 HIGHEST RN 1049627-95-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


=> d que sta l15
 L7 STR



VAR G1=O/S
 REP G2=(0-2) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
 L9 9009 SEA FILE=REGISTRY SSS FUL L7
 L13 STR



VAR G1=O/S
 REP G2=(0-2) C
 REP G3=(0-4) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E4 C E2 N AT 17

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L15 42 SEA FILE=REGISTRY SUB=L9 SSS FUL L13

100.0% PROCESSED 461 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:19:12 ON 15 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2008 VOL 149 ISS 12
FILE LAST UPDATED: 14 Sep 2008 (20080914/ED)


HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr l18 tot

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)
 (Uses)
 (drug candidate; prepn. of isoindoline derivs. as narcotic drugs)
 IT 701304-01-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of isoindoline derivs. as narcotic drugs)
 RN 701304-01-0 HCAPLUS
 CN Cyclopent[*f*]isoindol-1(2*H*)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)




RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10 / 534414

=> d bib abs hitstr 119 tot

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on SIN
 AN 2008:128596 HCAPLUS
 DN 148:1369264
 TI Novel water-soluble sedative-hypnotic agents: isoindolin-1-one derivatives
 AU Kanamitsu, Norimasa; Osaki, Takashi; Itsuji, Tataka; Yoshimura, Masakazu;
 TSujimoto, Hisashi; Soga, Manabu
 CS Central Research Laboratory, Maruishi Pharmaceutical Co., Ltd., 2-2-18
 Imazu-naka, Tsurumi-ku, Osaka, 538-0042, Japan
 SO Chemical & Pharmaceutical Bulletin (2007), 55(12), 1682-1688
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 GI

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors developed new i.v. sedative-hypnotic compds. with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. The authors synthesized approx. 170 derivs. and evaluated their hypnotic effects by i.v. administration of the compds. to mice. A series of the 2-phenyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]isoindolin-1-one analogs (I-IV) showed potent sedative-hypnotic activity with good water solubility and a wide safety margin. The hypnotic doses (HD50s) of these 4 compds. when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, resp., and the LDs (LD50s) were 88.67, 64.69, >120, and >120 mg/kg, resp. The therapeutic indexes (LD50/HD50) were 37.73, 34.05, >55.30, and >38.46, resp. Among these IV is being considered as the most potential candidate for clin. trials in humans.
 IT 870234-68-7P 1013427-48-9P
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (isoindolin-1-one derivs. as water-soluble sedative-hypnotic agents)
 RN 870234-68-7 HCAPLUS
 CN Cyclopent[*f*]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1013427-48-9 HCAPLUS
 CN Cyclopent[*f*]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-2-phenyl-, (-)- (CA INDEX NAME)

Rotation (-).

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on SIN
 AN 2006:268409 HCAPLUS
 DN 144:312115
 TI Preparation of 3-(piperazinylcarbonylmethyl)isoindole derivatives and anesthetic and sedative compositions containing them
 TN Kanemitsu, Norimasa; Itsuji, Hiroshi; Osaki, Takashi; Tsujimoto, Hisashi; Inoue, Keiji
 PA Maruishi Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKKXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP-2006076913	A	20060323	2004JP-000262082	20040909
PRAI 2004JP-000262082		20040909		
OS MAPPAT 144:312115				


 GI



AB Claimed are the derivs. I (R1 = Me, 2 R3 groups are bonded to form C2-4 alkylene; R2 = OH, C1-5 saturated aliphatic hydrocarbyl or C3-6 unsatd. hydrocarbyl substituted with C1-3 alkoxy or oxo; X = H, halo) and their salts. The compds. containing I (salts) and carriers are also claimed. The compds. are used by i.v. dosing for induction and maintenance of general anesthesia, management of sedation after operation or in intensive care, etc. Thus, 5,6-indandicarboxylic anhydride (preparation given) was reacted with 3-FC6H4NH2 in AcOH at 135° for 3 h to give 2-(3-fluorophenyl)-6,7-dihydrocyclopenta[*f*]isoindole-1,3(2H,5H)-dione, which was reduced and the resulting 2-(3-fluorophenyl)-3-hydroxy-3,5,6,7-tetrahydrocyclopenta[*f*]isoindol-1(2H)-one was reacted with (carboethoxymethylene)triphenylphosphorane to give 2-[2-(3-fluorophenyl)-3-oxo-1,2,3,5,6,7-hexahydrocyclopenta[*f*]isoindol-1-yl]acetic acid. This was resolved via diastereomeric salt formation with (S)-(-)-phenylethylamine and the (-)-isomer (0.15 g) was amidated with 1-(2-methyl-2-propenyl)piperazine to give 0.15 g (-)-I (R1R2 = (CH2)3, R2 = CH2CH:CH2, X = 3-F). Similarly prepared (-)-I.HCl (R1R2 = (CH2)3, R2 = CH2CH:CH2, X = 3-F) showed anesthetic activity with HD50 (min. dose to induce 230 s loss of righting reflex in 50% mice) of 1.74 mg/kg, vs. 14.72 mg/kg of propofol.
 IT 879895-96-2P 879895-97-2P 879895-98-4P
 879895-99-5P 879896-00-1P 879896-01-2P
 879896-02-3P 879896-03-4P 879896-04-5P
 879896-05-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (piperazinylcarbonylmethyl)isoindole derivs. and i.v. anesthetic and sedative compds. containing them)


RN 879895-96-2 HCAPLUS
 CN Cyclopent[*f*]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-[4-(2-methyl-2-propen-1-yl)-1-piperazinyl]-2-oxoethyl]-, (-)- (CA INDEX NAME)
 Rotation (-).

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 879895-97-3 HCAPLUS
 CN Cyclopent[*f*]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)


Rotation (-).



● HCl

RN 879895-98-4 HCAPLUS
 CN Cyclopent[*f*]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-2-phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).




● HCl

RN 879895-99-5 HCAPLUS
 CN Cyclopent[*f*]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-, (-)- (CA INDEX NAME)


Rotation (-).

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 879896-00-1 HCAPLUS
 CN Cyclopent[flisoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propyn-1-yl)-1-piperazinyl]ethyl]-2-phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)


Rotation (-).



● HCl

RN 879896-01-2 HCAPLUS
 CN Cyclopent[flisoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-(2-methoxyethyl)-1-piperazinyl)-2-oxoethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)


Rotation (-).



● HCl

RN 879896-02-3 HCAPLUS
 CN Cyclopent[flisoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-(2-hydroxyethyl)-1-piperazinyl)-2-oxoethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)


L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



● HCl

RN 879896-03-4 HCAPLUS
 CN Cyclopent[flisoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-[4-(2-methyl-2-propen-1-yl)-1-piperazinyl]-2-oxoethyl]-2-phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).




● HCl

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)

(CA INDEX NAME)


Rotation (-).



● HCl

RN 879896-03-4 HCAPLUS
 CN Cyclopent[flisoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-oxopropyl)-1-piperazinyl]ethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).



● HCl

RN 879896-04-5 HCAPLUS
 CN Cyclopent[flisoindol-1(2H)-one, 3-[2-[4-(2,2-dimethoxyethyl)-1-piperazinyl]-2-oxoethyl]-2-(3-fluorophenyl)-3,5,6,7-tetrahydro-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON SIN

AN 2005:1261054 HCAPLUS

DN 144:6817

TI Preparation of 2-phenyl-2,3-dihydroisindolin-1-one derivatives and neurogenic pain control agent compositions containing them
 IN Yoshimura, Masakazu; Kanamitsu, Norimasa; Itsuji, Yutaka; Osaki, Takashi; Kawashima, Motoko
 PA Maruishi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 53 pp.


COSEN: PIXXD2

DT Patent

LA Japanese

FAM, CMI 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005113501	A1	20051201	2005WO-JP0009361	20050523
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DM, EA, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, CH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
AU--2005245292	A1	20051201	2005AU-000245292	20050523
CA-----2563968	A1	20051201	2005CA-002563968	20050523
EP-----1749817	A1	20070207	2005EP-000741422	20050523
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, BR, HR, YU				
CN-----1956955	A	20070502	2005CN-000016837	20050523
BR--2005011546	A	20080102	2005BR-000011546	20050523
NO--2006004868	A	20070226	2006NO-000004868	20061025
IN--2006DN06250	A	20071130	2006IN-DN0006250	20061025
KR--2007018077	A	20070213	2006KR-000724401	20061121
MX--2006PA13766	A	20070208	2006MX-PA0013766	20061124
US--20080021042	A1	20080124	2007US-000587367	20070717
PPAI 2004JP-00015206	A	20040524		
2005WO-JP0009361	W	20050523		
OS MARPAT 144:6817				
GI				



AB A neurogenic pain control agent composition containing either a compound represented by the formula (I) [R1, R2 = Cl-6 alkyl or R1 and R2 are bonded together to form OCH2O, (CH2)3, CH2OCH2, or a 6-membered condensed ring containing conjugated double bond; X = halo, Cl-6 alkoxy or X together with Ph group to which X is bonded form 3,4-methylenedioxyphenyl; m = an integer of 0-2; Y = O, COR4, cyclopropylmethyl, piperidin-1-yl; wherein R4 = Cl-4 alkyl; X = O, S] or a salt thereof is disclosed. The compds. I possess fast analgesic activity against neuropathic pains without affecting motor function. Thus, 2-[2-(3-fluorophenyl)-5,6-dimethyl-3-oxo-2,3-dihydro-1H-isindol-1-yl]acetic acid 0.50, 1-methylpiperazine 0.16, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 0.31, 1-hydroxybenzotriazole hydrate 0.25 g were stirred in 40 mL THF at 25° for 16 h to give 5,6-dimethyl-2-[3-(3-fluorophenyl)-3-[[[4-methyl-1-piperazinyl]carbonyl]methyl]isindolin-1-one, 5,6-Dimethyl-2-[4-(3-fluorophenyl)-3-[[[4-methyl-1-piperazinyl]carbonyl]methyl]isindolin-1-one monohydrochloride (II) showed analgesic effect on mice at 30 mg/kg p.o. in

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 5 min after administration and required lower dosage than gabapentin.
 (-)-II stereoisomer was active but (+)-II stereoisomer was inactive. A
 tablet formulation contg. II was described.
 IT 870171-13-4P 870171-15-6P 870171-17-8P
 870171-19-0P 870171-21-4P 870171-23-6P
 870171-25-8P 870171-30-5P 870171-32-7P
 870171-34-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic
 pain control agent compns. containing them)
 RN 870171-13-4 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-
 (4-methyl-1-piperazinyl)-2-oxoethyl]-, hydrochloride (1:1), (-)- (CA
 INDEX NAME)


Rotation (-).



● HCl

RN 870171-15-6 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-
 1-yl)-1-piperazinyl]ethyl]-2-phenyl-, (-)- (CA INDEX NAME)


Rotation (-).




RN 870171-17-8 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propyn-
 1-yl)-1-piperazinyl]ethyl]-2-phenyl-, (-)- (CA INDEX NAME)

Rotation (-).


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 870171-30-5 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-
 1-yl)-1-piperazinyl]ethyl]-2-phenyl- (CA INDEX NAME)



RN 870171-32-7 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propyn-
 1-yl)-1-piperazinyl]ethyl]-2-phenyl- (CA INDEX NAME)




RN 870171-34-9 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3-[2-[4-(cyclopropylmethyl)-1-piperazinyl]-
 2-oxoethyl]-3,5,6,7-tetrahydro-2-phenyl- (CA INDEX NAME)




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 870171-19-0 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3-[2-[4-(cyclopropylmethyl)-1-piperazinyl]-
 2-oxoethyl]-3,5,6,7-tetrahydro-2-phenyl-, (-)- (CA INDEX NAME)


Rotation (-).




RN 870171-21-4 HCAPLUS
 CN 5H-1,3-Dioxolo[4,5-f]isoindol-5-one, 6,7-dihydro-7-[2-oxo-2-[4-(2-propen-1-
 yl)-1-piperazinyl]ethyl]-6-phenyl- (CA INDEX NAME)



RN 870171-23-6 HCAPLUS
 CN 5H-Furo[3,4-f]isoindol-5-one, 1,3,6,7-tetrahydro-7-[2-(4-methyl-1-
 piperazinyl)-2-oxoethyl]-6-phenyl- (CA INDEX NAME)



RN 870171-25-8 HCAPLUS
 CN 5H-Furo[3,4-f]isoindol-5-one, 1,3,6,7-tetrahydro-7-[2-oxo-2-[4-(2-propen-1-
 yl)-1-piperazinyl]ethyl]-6-phenyl- (CA INDEX NAME)



```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


FILE 'USPAT2' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l20 tot
```

L20 ANSWER 1 OF 2 USPATFULL on STN
 AN 2008:23861 USPATFULL
 TI Composition For Controlling Neuropathic Pain
 IN Masakazu, Yoshimura, Kobe-shi, Hyogo, JAPAN
 PA MARUISEI PHARMACEUTICAL CO., LTD., Osaka-shi, Osaka, JAPAN, 541-0044
 (non-U.S. corporation)
 PI US-20080021042 A1 20080124
 AI 200505-000587367 A1 20050523 (11)
 2005WO-JP0009361 20050523
 20070717 PCT 371 date
 PRAI 2004JP-000153206 20040524
 DI Utility
 FS APPLICATION
 LREP HAMRE, SCHUMANN, MUELLER & LARSON, P.C., P.O. BOX 2902, MINNEAPOLIS, MN,
 55402-0902, US
 CLMN Number of Claims: 15
 ECL Exemplary Claim: 1-11
 DRWN 8 Drawing Page(s)
 LN.CNT 860
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The instant application provides a pharmaceutical composition for
 controlling neuropathic pain, which comprises a compound of formula:
 ##STR1## or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


II 701304-01-OP 701304-04-3P 701304-06-5P
 870171-13-4P 870171-15-6P 870171-17-8P
 870171-19-0P 870171-21-4P 870171-23-6P
 870171-25-8P 870171-30-5P 870171-32-7P
 870171-34-9P
 (preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic
 pain control agent compns. containing them)
 II 701304-01-OP
 (preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic
 pain control agent compns. containing them)
 RN 701304-01-0 USPATFULL
 CN cyclopent[*f*]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-
 (4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)



L20 ANSWER 2 OF 2 USPATFULL on STN
 AN 2006:61222 USPATFULL
 TI Isoindoline derivative
 IN Toyooka, Kouhei, Osaka-fu, JAPAN
 Nanamitsu, Norimasa, Takarazuka-shi, JAPAN
 Yoshimura, Masakazu, Hyogo-ken, JAPAN
 Kuriyama, Haruo, Osaka-fu, JAPAN
 Tamura, Takashi, Osaka-fu, JAPAN
 PA MARUISEI PHARMACEUTICAL CO., LTD (non-U.S. corporation)
 PI US-20060052392 A1 20060309
 AI 200305-000534414 A1 20031125 (10)
 2003WO-JP0014986 20031125
 20050511 PCT 371 date
 PRAI 2002JP-000342399 20021126
 DI Utility
 FS APPLICATION
 LREP FOLEY AND LARDNER LLP, SUITE 500, 3000 K STREET NW, WASHINGTON, DC,
 20007, US
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1971
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Provided is a novel isoindoline compound of the formula (I): ##STR1##
 The compound is useful for anesthesia by inducing sedation in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

II 701304-01-OP 701304-02-1P 701304-03-2P
 701304-04-3P 701304-05-4P 701304-06-5P
 701304-22-5P 701304-23-6P 701304-24-7P
 701304-25-8P 701304-26-9P 701304-27-0P
 701304-32-7P
 (drug candidate; preparation of isoindoline derivs. as narcotic drugs)
 II 701304-01-OP
 (drug candidate; preparation of isoindoline derivs. as narcotic drugs)
 RN 701304-01-0 USPATFULL
 CN cyclopent[*f*]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-
 (4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:46:28 ON 15 SEP 2008)

FILE 'HCAPLUS' ENTERED AT 10:46:39 ON 15 SEP 2008

L1 1 US20060052392 /PN

FILE 'REGISTRY' ENTERED AT 10:47:02 ON 15 SEP 2008

FILE 'HCAPLUS' ENTERED AT 10:47:02 ON 15 SEP 2008

L2 TRA L1 1- RN : 284 TERMS

FILE 'REGISTRY' ENTERED AT 10:47:03 ON 15 SEP 2008

L3 284 SEA L2

L4 254 L3 AND NRS>=2

L5 17 L4 AND NRRS>=3

SAV TEM J414C4/A L***

L6 STR L***

L7 STR L***

L8 32 L7

L9 9009 L7 FULL

SAV TEM J414C4/A L9

L10 17 L9 AND L3

L11 13 L10 AND NC2NC2/ES

L12 8992 L9 NOT L10-11

L13 STR L6

L14 0 L13 SAM SUB=L9

L15 42 L13 FULL SUB=L9

L16 13 L15 AND L3

L17 29 L15 NOT L16

FILE 'HCAPLUS' ENTERED AT 11:18:03 ON 15 SEP 2008

L18 3 L16

L19 3 L17

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:18:10 ON 15 SEP 2008

L20 2 L16-17

FILE 'HCAOLD' ENTERED AT 11:18:38 ON 15 SEP 2008

L21 0 L16

L22 0 L17

=>